EMGALITY 120 mg/mL (Galcanezumab-Gnlm INJECTION, SOLUTION) 120 mg/mL

Galcanezumab-gnlm is a humanized monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand, blocking its binding to the receptor. This action is believed to reduce the frequency and severity of migraine and cluster headaches by modulating the activity of CGRP, a peptide involved in pain signaling and vascular dilation.

The dosage of EMGALITY 120 mg/mL is determined by a healthcare provider based on the specific condition being treated. For migraine, the recommended dosage is a 240 mg loading dose (administered as two consecutive injections of 120 mg each), followed by monthly doses of 120 mg. For episodic cluster headache, the recommended dosage is 300 mg (administered as three consecutive injections of 100 mg each) at the onset of the cluster period, and then monthly until the end of the cluster period.

The safety of EMGALITY 120 mg/mL during pregnancy or breastfeeding has not been established. It is important to consult with a healthcare provider to discuss the potential risks and benefits before using this medication during pregnancy or while breastfeeding.

To order EMGALITY 120 mg/mL from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will then reply with pricing, availability, shipping (including cold-chain where relevant), and the import paperwork.

EMGALITY 120 mg/mL is a CGRP antagonist specifically developed for the preventive treatment of migraine. Compared to other migraine treatments, it offers a targeted approach by blocking the CGRP ligand, which is believed to play a key role in migraine pathogenesis. The choice of treatment depends on individual patient factors and should be discussed with a healthcare provider.

EMGALITY 120 mg/mL should be stored refrigerated at 2-8°C (36-46°F) in the original carton to protect it from light. It should not be frozen or shaken. The medication may be stored out of refrigeration in the original carton at temperatures up to 30°C (86°F) for up to 7 days. Once stored out of refrigeration, it should not be placed back in the refrigerator. If these conditions are exceeded, the medication must be discarded.

EMGALITY 120 mg/mL is administered subcutaneously. The injection can be given in the abdomen, thigh, back of the upper arm, or buttocks. It is important to follow the instructions provided by the healthcare provider or the product labeling for proper administration.

The most serious risks associated with EMGALITY 120 mg/mL include serious hypersensitivity reactions, such as anaphylaxis and angioedema, constipation with serious complications, new-onset or worsening of pre-existing hypertension, and new-onset or worsening of pre-existing Raynaud's phenomenon. Patients should be monitored for these potential adverse effects.

EMGALITY 120 mg/mL is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients. Patients should consult with their healthcare provider to determine if this medication is appropriate for them, considering their medical history and current medications.